



PTO/SB/30 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**REQUEST  
FOR  
CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**  
Address to:  
Commissioner for Patents  
Box RCE  
Washington, DC 20231

<b>Application Number</b>	09/416,267-Conf. #5938
<b>Filing Date</b>	October 12, 1999
<b>First Named Inventor</b>	Kui Su
<b>Group Art Unit</b>	1646
<b>Examiner Name</b>	P. Mertz
<b>Attorney Docket No.</b>	PF270P1

**This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.**

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

#22  
J.J.  
5/21/03

**1. Submission required under 37 CFR 1.114**

- a.  Previously submitted
  - i.  Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on \_\_\_\_\_ (Any unentered amendment(s) referred to above will be entered).
  - ii.  Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
  - iii.  Other \_\_\_\_\_
- b.  Enclosed
  - i.  Response
  - ii.  Affidavit(s)/Declaration(s)
  - iii.  Information Disclosure Statement (IDS)
  - iv.  Other Fee Transmittal; Exhibits A-D

**RECEIVED**

MAY 14 2003

TECH CENTER 1600/2900


**2. Miscellaneous**

- a.  Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b.  Other Return Receipt Postcard

**3. Fees** The RCE fee under 37 CFR 1.17 (e) is required by 37 CFR 1.114 when the RCE is filed.

- a.  The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 08-3425
  - i.  RCE fee required under 37 CFR 1.17(e)
  - ii.  Extension of time fee (37 CFR 1.136 and 1.17)
  - iii.  Other \_\_\_\_\_
- b.  Check in the amount of \$ \_\_\_\_\_ enclosed
- c.  Payment by credit card (Form PTO-2038 enclosed)

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	Janet M. Martineau	Registration No. (Attorney/Agent)	46,903
Signature		Date	May 9, 2003

05/12/2003 SSESHE1 00000123 083425 09416267

01 FC:1801 750.00 CH



VIA HAND DELIVERY MAY 9<sup>TH</sup>, 2003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: SU et al.

Application Serial No.: 09/416,267

Art Unit: 1646

#23

Filed: October 12, 1999

Examiner: Mertz, P.

MJ

For: Human Cytokine Polypeptide

Attorney Docket No.: PF270P1

5/21/03

**RESPONSE UNDER 37 C.F.R. § 1.116 TO PAPER NO. 20**

Commissioner for Patents

Washington, D.C. 20231

Sir:

In response to the Final Official action mailed February 10, 2003 (Paper No. 20), please consider the following remarks. Submitted concurrently herewith is: (a) a Fee Transmittal sheet; (b) a Request for Continued Examination; and (c) Exhibits A-D.

Applicants hereby request that the following remarks be entered into the above-identified application.

**Remarks**

Claims 25-79 are pending in this application.

**RECEIVED**

MAY 14 2003

TECH CENTER 1600/2900